INZY (inozyme.com) Earnings per share growth this year

Inozyme Pharma, Inc. (INZY) minimizes risks by developing high-margin drugs to combat tissue mineralization pathologies. Annual EPS fluctuations illustrate the price action in response to this strategy, with the metric settling at 7.80. Stable revenue is driven by monopoly demand for enzyme therapy for rare diseases, while business development relies on a dedicated staff of leading geneticists and biochemists.

INZY (Inozyme Pharma) Earnings per share growth in current year history from 07/04/2022 to 07/12/2025

Financial and market metric breakdowns for Inozyme Pharma (INZY)

- stock value and consensus price forecast:

Market Price Inozyme Pharma Inc.|INZY - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Inozyme Pharma Inc.|INZY - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value of a Share Inozyme Pharma|INZY - Company Book Value|Market Capitalization to Net Assets inozyme.com|INZY - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

INZY - Net Profit|Company Profit Forecast Inozyme Pharma, Inc.|INZY - Price to Earnings Ratio|Price to Future Earnings Ratio Inozyme|INZY - Price/Earnings to Growth Ratio|Company Value to EBITDA Inozyme Pharma Inc.|INZY - Operating profit before deduction of amortization|Earnings per one share for the last 12 months Inozyme Pharma|INZY - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months inozyme.com|INZY - Earnings per share growth in current year|Expected earnings per share growth for next year Inozyme Pharma, Inc.

- revenue and sales proceeds data:

INZY - Revenue and Sales Volume|Company Expected Sales Volume Inozyme Pharma, Inc.|INZY - Market Cap to Revenue|Forward Price to Sales Inozyme Pharma, Inc.|INZY - Sales Growth YoY (Last Twelve Months)

Basic company analysis:inozyme.com (INZY)

Investors are assessing the resilience of Inozyme Pharma, Inc. (INZY) through the dynamics of its financial performance. This metric measures the annual percentage change in net income per share, allowing investors to filter out market noise and determine the real growth rate of earnings. An analysis of the annual percentage increase in net income per share confirms how the diversification of rare disease therapies mitigates regulatory risks, impacting the fundamental value of the business.

Main competitors